---
title: "HOOKIPA Pharma Inc. (HOOK.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/HOOK.US.md"
symbol: "HOOK.US"
name: "HOOKIPA Pharma Inc."
industry: "生物技術"
---

# HOOKIPA Pharma Inc. (HOOK.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.hookipapharma.com](https://www.hookipapharma.com) |

## Company Profile

HOOKIPA Pharma Inc.是一家臨床階段的生物制藥公司，開發基于其專有的阿瑞納病毒平台的針對傳染病的免疫治療藥物。該公司的免疫腫瘤學管線包括 HB-700，這是一種新型的下一代多 KRAS 突變靶向研究性免疫療法，用于治療包括肺癌、結直腸癌和胰腺癌在內的 KRAS 突變癌症；Eseba-vec，一種正在臨床開發中的研究性免疫治療藥物，用于治療人乳頭瘤病毒 16 型（HPV16+）陽性的頭頸癌，已完成 1/2 期臨床試驗的入組；以及 HB-300，針對自我抗原用于治療前列腺癌。該公司還在開發 HB-400 用于治療乙型肝炎，目前處于 I 期臨床試驗階段；以及 HB-500 用于治療人...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: E (0.80)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 388 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -82.54% |  |
| Net Profit YoY | -54.29% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.38 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 13.12M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 9.35M |  |


**Multi Score**: E

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -105.79% | E |
| Profit Margin | -784.01% | E |
| Gross Margin | -541.67% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -82.54% | E |
| Net Profit YoY | -54.29% | D |
| Total Assets YoY | -58.01% | E |
| Net Assets YoY | -67.39% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -12.75% | D |
| OCF YoY | -82.54% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.09 | E |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 44.36% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - HOOKIPA Pharma Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-105.79%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-784.01%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-541.67%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-82.54%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-54.29%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-58.01%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-67.39%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-12.75%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-82.54%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.09",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "44.36%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.18 | 94/604 | - | - | - |
| PB | 0.38 | 23/604 | 0.39 | 0.34 | 0.31 |
| PS (TTM) | 1.40 | 35/604 | 1.43 | 1.22 | 0.40 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/HOOK.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/HOOK.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/HOOK.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.